Skip to main content
AMPH logo

AMPH

Amphastar Pharmaceuticals, Inc.
$18.72 -0.30 (-1.58%) At close · Jul 10
Market Cap
$825.42M
Shares
44,092,919

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$18.72 Open$18.97 Day$18.61–19.15 52W$16.65–31.26 Avg vol 30d521K Short int3.8M · 8.7% float · 5.2d Short vol29% Last earningsMay 7, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 7
Up next
Next earnings call
Aug 7, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 7, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −20%
      below
      Price vs 50-day avg −5%
      below
      RSI (14) 43
      neutral
      MACD trend Negative
      52-week position 14%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −8%
      trailing
      6-month return −28%
      trailing
      YTD return −30%
      this year
      Relative strength −37%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $20 › 200d $23 — 200d above 50d
      Institutional flow Distributing
      12 of 214 funds reported for Jun 30 · net -1.6K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      8.72% of float · ▲ +1.2% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      214 holders — near 3-yr low, contrarian setup
      Squeeze score 68
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth −2%
      Y/Y
      Gross margin 49%
      contracting
      EPS growth −34%
      Y/Y
      Free cash flow $121.2M
      Valuation P/E 11.3
      below peers
      Buyback $50.0M
      remaining
      Balance sheet $129.9M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 56%
      annualized · 1-yr
      Max drawdown −45%
      past year
      ATR 4.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −20% Bearish
      Price vs 50-day avg
      −5% Neutral
      RSI (14)
      43 Neutral
      MACD trend
      Negative Bearish
      52-week position
      14% Bearish
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $20 › 200d $23 — 200d above 50d
      Institutional flow Distributing
      12 of 214 funds reported for Jun 30 · net -1.6K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      8.72% of float · ▲ +1.2% MoM · 5.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      214 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      52-wk low $17 Now $19 · 14% 52-wk high $31
      vs 200-day avg -20% vs 50-day avg -5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      AMPH
      Amphastar Pharmaceuticals, Inc.
      this stock
      $825.42M -30.1% -1.7% 11.3 8.7%
      TAK
      Takeda Pharmaceutical Co Ltd
      $52.88B +6.2% 0.2%
      GALDY
      Galderma Group AG/ADR
      $50.15B +3.2% 0.0%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      $45.13B 0.0%
      HLN
      Haleon plc
      $42.98B -3.5% 0.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      213
      % held
      71.8%
      Reported
      12 of 214
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      255
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.8M
      Days to cover
      5.2d
      Change
      +46.0K sh
      View
      Short Volume
      Short vol %
      29%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.7K
      Value
      $33.8K
      As of
      May 29, 2026
      View
      Off-Exchange
      Off-exchange %
      47.9%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $719.9M
      Net income (FY)
      $98.1M
      EPS diluted
      $2.03
      View
      Buybacks
      Authorized
      $485.0M
      Remaining
      $50.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 8, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $333.0K
      Shares
      4.2K
      Filed
      Dec 11, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      AMPH -4.7% -7.7% -28.0% -7.2% -30.1%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY -6.1% -11.8% -37.1% -8.3% -40.8%

      Capital returns

      Buyback program · as of Mar 16, 2026
      Authorized
      $485.00M
      Spent (derived)
      $435.00M
      Remaining
      $50.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1297184 CUSIP 03209R103 13F (30d) 13 filings 12 filers Visit website Investor relations